Nimotuzumab: Phase II discontinued

YM discontinued a double-blind, placebo-controlled, international Phase II trial evaluating nimotuzumab plus radiotherapy in 128 patients due to slow enrollment rates. In February, the biotech said it was evaluating whether to discontinue the trial and focus on advanced trials involving partner Daiichi Sankyo, including a planned pivotal trial of nimotuzumab in gastric cancer (see BioCentury, Feb 21). ...